Treatment of Breast Cancer with Grave Signs

Introduction to Treatment Approach

The primary treatment goal for breast cancer with grave signs is palliation to maintain and improve quality of life, using systemic therapy tailored to hormone receptor and HER2 status, combined with radiation therapy for symptomatic control, as recommended by the European Society for Medical Oncology 1, 2

For hormone receptor-positive disease, the European Society for Medical Oncology recommends starting with endocrine therapy unless biologically aggressive disease mandates rapid response, with options including third-generation aromatase inhibitors for postmenopausal patients 1, 3
For hormone receptor-negative or aggressive disease, the European Society for Medical Oncology suggests chemotherapy as the primary systemic approach, with a preferred strategy of sequential single-agent chemotherapy producing equivalent overall survival to combination regimens with significantly less toxicity 1, 2
For HER2-positive disease, the European Society for Medical Oncology recommends adding trastuzumab to chemotherapy, avoiding anthracyclines with trastuzumab, and considering lapatinib as an alternative targeted agent 1, 3

The European Society for Medical Oncology indicates palliative radiotherapy for bone metastases, brain metastases, and soft tissue masses, with options including limited-field external beam, hemi-body irradiation, and radioactive isotopes 1, 2
The European Society for Medical Oncology suggests considering surgical removal of the primary tumor for limited metastatic presentations, with retrospective data suggesting a significant survival benefit 1, 2

The European Society for Medical Oncology recommends monitoring patients frequently, every 2-3 months if on endocrine therapy and every 1-2 chemotherapy cycles, with immediate evaluation if progression is suspected 4
The European Society for Medical Oncology suggests using radiological examinations, serum tumor markers, and clinical assessment for response evaluation, with caution when using bone scans due to potential flare response mimicking progression 4

The European Society for Medical Oncology emphasizes the importance of a multidisciplinary team approach, including medical, radiation, and surgical oncologists, imaging specialists, palliative care specialists, and psychosocial support 1, 2
The European Society for Medical Oncology recommends patient-centered decision making from treatment initiation, discussing realistic treatment goals, encouraging active patient participation, and considering patient preferences regarding treatment options and administration methods 1, 2

Radiation therapy is recognized by the European Society for Medical Oncology (ESMO) as an essential component of palliative care for symptomatic metastatic breast cancer lesions, providing rapid symptom relief and local tumor control. 5
For patients with symptomatic mediastinal metastases (e.g., dyspnea, superior vena cava compression), palliative radiation aims to alleviate compressive symptoms and improve quality of life. 5

Good performance status (e.g., ECOG 0‑1) predicts better tolerance of aggressive local therapy and is a key criterion for offering definitive mediastinal radiation. 6
In oligometastatic disease (≤3‑4 metastatic sites) with a prolonged disease‑free interval, aggressive local treatment—including radiation—may be considered to prolong disease control. 6

PET‑CT is recommended to confirm isolated mediastinal involvement before pursuing curative‑intent radiation in oligometastatic patients. [6][7]
Modern CT‑based treatment planning is mandatory to spare critical mediastinal structures (heart, lungs, esophagus, spinal cord) and to minimize cardiac and pulmonary toxicity. 8

A conventional palliative regimen of 50 Gy delivered in 25 fractions is supported as a reasonable dose for symptomatic mediastinal disease. 5
Precision techniques such as intensity‑modulated radiation therapy (IMRT) or volumetric‑modulated arc therapy (VMAT) are advised to achieve effective local control while limiting dose to adjacent organs. 8

Concurrent administration of endocrine therapy (for hormone‑receptor‑positive disease) or trastuzumab (for HER2‑positive disease) with mediastinal radiation is considered safe and does not increase acute toxicity. 8
Systemic therapy selection should continue to be guided by tumor biology (hormone‑receptor status, HER2 status) irrespective of radiation delivery. 5

When the mediastinum has previously received radiation (e.g., prior chest‑wall irradiation), re‑irradiation decisions must weigh the interval since the first course, cumulative dose constraints, and existing late toxicities. 9

The above recommendations are based on guideline consensus (ESMO) and expert opinion derived from retrospective series and multidisciplinary guidelines; they are classified as Level III evidence (expert consensus).

All facts are drawn from cited sources and presented in English with patient identifiers generalized.